GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-  
B1200 PRX-08066Summary: 5-HT2BR antagonist -  
B1338 Maprotiline HClSummary: Selective noradrenalin re-uptake inhibitor -  
B6841 CV 1808Summary: Adenosine A2 receptor agonist -  
B7689 (±)-SLV 319Summary: CB1 receptor antagonist,potent and selective -  
B1199 TandospironeSummary: Anxiolytic and antidepressant reagent -  
B1337 L-AdrenalineTarget: adrenergic receptorSummary: Adrenergic receptor agonist -  
B6839 2-Chloro-N6-cyclopentyladenosineSummary: adenosine A1 receptor agonist, potent and selective -  
B7579 MJ 15Summary: CB1 receptor antagonist -  
B1198 CisaprideTarget: Voltage-gated Potassium (KV) Channels|5-HT4 ReceptorSummary: 5-HT4 receptor agonist -  
B1336 Isoprenaline HClSummary: β-adrenergic receptor agonist 
